UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

GP369, an FGFR2-IIIb-Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling

Cancer research (Chicago, Ill.), 2010-10, Vol.70 (19), p.7630-7639

2010

Volltextzugriff (PDF)

The colonization of land by animals: molecular phylogeny and divergence times among arthropods

BMC biology, 2004-01, Vol.2 (1), p.1-1, Article 1

2004

Volltextzugriff (PDF)

Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage

Pigment cell and melanoma research, 2008-08, Vol.21 (4), p.457-463

2008

Volltextzugriff (PDF)

A Molecular Phylogeny of Reptiles

Science (American Association for the Advancement of Science), 1999-02, Vol.283 (5404), p.998-1001

1999

Volltextzugriff (PDF)

Chromatin structure analyses identify miRNA promoters

Genes & development, 2008-11, Vol.22 (22), p.3172-3183

2008

Volltextzugriff (PDF)

Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

Molecular cancer therapeutics, 2021-05, Vol.20 (5), p.885-895

2021

Volltextzugriff (PDF)

The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b

Molecular cancer therapeutics, 2021-05, Vol.20 (5), p.896-905

2021

Volltextzugriff (PDF)

Abstract 596: Optimization of lead antibody selection for XMT-1522, a novel, highly potent HER2-targeted antibody-drug conjugate (ADC)

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.596-596

2016

Volltextzugriff (PDF)

CFT8634, a Clinical Stage BRD9 Bi DAC™ Degrader, Is Active in a Subset of Multiple Myeloma Cell Line Models and Synergistic When Combined with Pomalidomide

Blood, 2023-11, Vol.142 (Supplement 1), p.6594-6594

2023

Volltextzugriff (PDF)

Abstract 6046: CFT8634, a BRD9 BiDAC™ degrader, is active in a subset of multiple myeloma cell line models and synergistic when combined with pomalidomide or dexamethasone

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.6046-6046

2024

Volltextzugriff (PDF)

Abstract 1658: CFT1946, a potent, selective BRAF V600X mutant-specific degrader demonstrates superior activity as a single agent to clinically approved BRAF inhibitors and standard of care combinations in preclinical models of BRAF V600X melanoma, CRC, NSCLC, and brain metastasis

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.1658-1658

2024

Volltextzugriff (PDF)

Abstract 2670: Combination of anti-HER2 ADC XMT-1522 and checkpoint inhibitor pembrolizumab for treatment of NSCLC in preclinical models

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2670-2670

2017

Volltextzugriff (PDF)

Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.ND09-ND09

2022

Volltextzugriff (PDF)

Abstract 2645: Advantages of polyacetal polymer-based ADCs: Application to low expression targets

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2645-2645

2014

Volltextzugriff (PDF)

Abstract C238: Polyacetal polymer-based anti-HER2 antibody-drug conjugate employing cysteine bioconjugation through thioether linkage allows a high drug loading of dolastatin-derived payload with excellent pharmacokinetics and potent anti-tumor activity

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.C238-C238

2013

Volltextzugriff (PDF)

Abstract 4586: Essential role of fibroblast growth factor receptor 2 (FGFR2) in tumorigenesis of human cancers with activated FGFR2 signaling demonstrated by functional blocking antibodies

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.4586-4586

2011

Volltextzugriff (PDF)

MITF: Critical Regulator of the Melanocyte Lineage

From Melanocytes to Melanoma, p.51-69

Volltextzugriff (PDF)

Clinical Practice Guideline: Sudden Hearing Loss (Update)

Otolaryngology-head and neck surgery, 2019-08, Vol.161 (1_suppl), p.S1-S45

2019

Volltextzugriff (PDF)

Rethinking the clinical utility of distortion-product otoacoustic emission (DPOAE) signal-to-noise ratio

International journal of audiology, 2024-07, Vol.ahead-of-print (ahead-of-print), p.1-9

2024

Volltextzugriff (PDF)

Clinical Practice Guideline: Sudden Hearing Loss (Update) Executive Summary

Otolaryngology-head and neck surgery, 2019-08, Vol.161 (2), p.195-210

2019

Volltextzugriff (PDF)

Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma

Annals of surgery, 2016-12, Vol.264 (6), p.1073-1081

2016

Volltextzugriff (PDF)

Emerging Distortion Product Otoacoustic Emission Techniques to Identify Preclinical Warning Signs of Basal Cochlear Dysfunction Due to Ototoxicity

Applied sciences, 2019-08, Vol.9 (15), p.3132

2019

Volltextzugriff (PDF)

Serial Monitoring of Otoacoustic Emissions in Clinical Trials

Otology & neurotology, 2016-09, Vol.37 (8), p.e286-e294

2016

Volltextzugriff (PDF)

Single‐cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions

The Journal of pathology, 2019-03, Vol.247 (3), p.347-356

2019

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(30)
Buchkapitel
(1)

Sprache

Englisch
(31)

Erscheinungsjahr

n.n

Thema

Science & Technology
(15)
Life Sciences & Biomedicine
(13)
Humans
(12)
Animals
(6)
Female
(6)
Oncology
(5)
Otorhinolaryngology
(5)
Male
(4)
Mice
(4)
Cell Line, Tumor
(3)
Mice, Scid
(3)
Middle Aged
(3)
Otoacoustic Emissions
(3)
Surgery
(3)
Adult
(2)
Aged
(2)
Aged, 80 And Over
(2)
Audiology
(2)
Audiology & Speech-Language Pathology
(2)
Biological And Medical Sciences
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

GP369, an FGFR2-IIIb-Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling

The colonization of land by animals: molecular phylogeny and divergence times among arthropods

Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage

A Molecular Phylogeny of Reptiles

Chromatin structure analyses identify miRNA promoters

Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b

Abstract 596: Optimization of lead antibody selection for XMT-1522, a novel, highly potent HER2-targeted antibody-drug conjugate (ADC)

CFT8634, a Clinical Stage BRD9 Bi DAC™ Degrader, Is Active in a Subset of Multiple Myeloma Cell Line Models and Synergistic When Combined with Pomalidomide

Abstract 6046: CFT8634, a BRD9 BiDAC™ degrader, is active in a subset of multiple myeloma cell line models and synergistic when combined with pomalidomide or dexamethasone

Abstract 1658: CFT1946, a potent, selective BRAF V600X mutant-specific degrader demonstrates superior activity as a single agent to clinically approved BRAF inhibitors and standard of care combinations in preclinical models of BRAF V600X melanoma, CRC, NSCLC, and brain metastasis

Abstract 2670: Combination of anti-HER2 ADC XMT-1522 and checkpoint inhibitor pembrolizumab for treatment of NSCLC in preclinical models

Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers

Abstract 2645: Advantages of polyacetal polymer-based ADCs: Application to low expression targets

Abstract C238: Polyacetal polymer-based anti-HER2 antibody-drug conjugate employing cysteine bioconjugation through thioether linkage allows a high drug loading of dolastatin-derived payload with excellent pharmacokinetics and potent anti-tumor activity

Abstract 4586: Essential role of fibroblast growth factor receptor 2 (FGFR2) in tumorigenesis of human cancers with activated FGFR2 signaling demonstrated by functional blocking antibodies

MITF: Critical Regulator of the Melanocyte Lineage

Clinical Practice Guideline: Sudden Hearing Loss (Update)

Rethinking the clinical utility of distortion-product otoacoustic emission (DPOAE) signal-to-noise ratio

Clinical Practice Guideline: Sudden Hearing Loss (Update) Executive Summary

Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma

Emerging Distortion Product Otoacoustic Emission Techniques to Identify Preclinical Warning Signs of Basal Cochlear Dysfunction Due to Ototoxicity

Serial Monitoring of Otoacoustic Emissions in Clinical Trials

Single‐cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions

Roadmap to a Global Template for Implementation of Ototoxicity Management for Cancer Treatment

Suchergebnisse filtern